Michelle J Groome1, Elizabeth R Zell2, Fatima Solomon3, Susan Nzenze3, Umesh D Parashar4, Alane Izu3, Shabir A Madhi5. 1. Medical Research Council, Respiratory and Meningeal Pathogens Research Unit Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 2. Stat-Epi Associates Inc, West Palm Beach, Florida. 3. Medical Research Council, Respiratory and Meningeal Pathogens Research Unit Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases. 4. Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 5. Medical Research Council, Respiratory and Meningeal Pathogens Research Unit Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases National Institute for Communicable Diseases, National Health Laboratory Service, Sandringham, South Africa.
Abstract
BACKGROUND: The public health impact of rotavirus vaccination in African settings with a high human immunodeficiency virus (HIV) infection prevalence is yet to be established. We evaluated trends in all-cause diarrheal hospitalizations in Soweto, Johannesburg, before and after the introduction of rotavirus vaccine into South Africa's national immunization program in August 2009. METHODS: Hospitalizations in children <5 years of age with a diagnosis of diarrhea, defined byInternational Classification of Diseases, Tenth Revisioncodes A00-A05, A06.0-A06.3, A06.9, A07.0-A07.2, A07.9, and A08-A09, were identified at the Chris Hani Baragwanath Academic Hospital from 1 January 2006 to 31 December 2014. The median annual prevaccine (2006-2008) hospitalization incidence was compared to that of the vaccine era (2010-2014), and stratified by age group and HIV infection status. RESULTS: Incidence reductions (per 1000 population) were greatest in children aged <12 months: 54.4 in the prevaccine era vs 30.0, 23.6, 20.0, 18.8, and 18.9 in the postvaccine years 2010-2014, respectively (a 44.9%-65.4% reduction). Lower incidence reductions (39.8%-49.4%) were observed among children aged 12-24 months from the second year post-vaccine introduction onward. Reductions were observed in both HIV-infected and HIV-uninfected children. There was a change in the seasonal pattern of diarrheal hospitalizations post-vaccine introduction, with flattening of the autumn-winter peaks seen in the prevaccine years. CONCLUSIONS: An accelerated and sustained decline in all-cause diarrheal hospitalizations, temporally associated with rotavirus vaccine introduction, was observed in children <2 years of age. However, the impact of other interventions such as improved sanitation and changes in HIV management cannot be discounted. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: The public health impact of rotavirus vaccination in African settings with a high human immunodeficiency virus (HIV) infection prevalence is yet to be established. We evaluated trends in all-cause diarrheal hospitalizations in Soweto, Johannesburg, before and after the introduction of rotavirus vaccine into South Africa's national immunization program in August 2009. METHODS: Hospitalizations in children <5 years of age with a diagnosis of diarrhea, defined byInternational Classification of Diseases, Tenth Revisioncodes A00-A05, A06.0-A06.3, A06.9, A07.0-A07.2, A07.9, and A08-A09, were identified at the Chris Hani Baragwanath Academic Hospital from 1 January 2006 to 31 December 2014. The median annual prevaccine (2006-2008) hospitalization incidence was compared to that of the vaccine era (2010-2014), and stratified by age group and HIV infection status. RESULTS: Incidence reductions (per 1000 population) were greatest in children aged <12 months: 54.4 in the prevaccine era vs 30.0, 23.6, 20.0, 18.8, and 18.9 in the postvaccine years 2010-2014, respectively (a 44.9%-65.4% reduction). Lower incidence reductions (39.8%-49.4%) were observed among children aged 12-24 months from the second year post-vaccine introduction onward. Reductions were observed in both HIV-infected and HIV-uninfectedchildren. There was a change in the seasonal pattern of diarrheal hospitalizations post-vaccine introduction, with flattening of the autumn-winter peaks seen in the prevaccine years. CONCLUSIONS: An accelerated and sustained decline in all-cause diarrheal hospitalizations, temporally associated with rotavirus vaccine introduction, was observed in children <2 years of age. However, the impact of other interventions such as improved sanitation and changes in HIV management cannot be discounted. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Oikwathaile Onosi; Nicole S Upfold; Michael D Jukes; Garry A Luke; Caroline Knox Journal: Food Environ Virol Date: 2018-12-17 Impact factor: 2.778
Authors: N A Page; L M Seheri; M J Groome; J Moyes; S Walaza; J Mphahlele; K Kahn; C N Kapongo; H J Zar; S Tempia; C Cohen; S A Madhi Journal: Vaccine Date: 2017-10-27 Impact factor: 3.641
Authors: Christabel C Enweronu-Laryea; George Armah; Kwamena W Sagoe; Daniel Ansong; Emmanuel Addo-Yobo; Stanley K Diamenu; Jason M Mwenda; Umesh D Parashar; Jacqueline E Tate Journal: Vaccine Date: 2018-05-08 Impact factor: 3.641
Authors: Darwin J Operario; James A Platts-Mills; Sandrama Nadan; Nicola Page; Mapaseka Seheri; Jeffrey Mphahlele; Ira Praharaj; Gagandeep Kang; Irene T Araujo; Jose Paulo G Leite; Daniel Cowley; Sarah Thomas; Carl D Kirkwood; Francis Dennis; George Armah; Jason M Mwenda; Pushpa Ranjan Wijesinghe; Gloria Rey; Varja Grabovac; Chipo Berejena; Chibumbya J Simwaka; Jeannine Uwimana; Jeevan B Sherchand; Hlaing Myat Thu; Geethani Galagoda; Isidore J O Bonkoungou; Sheriffo Jagne; Enyonam Tsolenyanu; Amadou Diop; Christabel Enweronu-Laryea; Sam-Aliyah Borbor; Jie Liu; Timothy McMurry; Benjamin Lopman; Umesh Parashar; John Gentsch; A Duncan Steele; Adam Cohen; Fatima Serhan; Eric R Houpt Journal: J Infect Dis Date: 2017-07-15 Impact factor: 5.226
Authors: Syed M Satter; Negar Aliabadi; Catherine Yen; Paul A Gastañaduy; Makhdum Ahmed; Abdullah Mamun; Khaleda Islam; Meerjady S Flora; Mahmudur Rahman; K Zaman; Mustafizur Rahman; James D Heffelfinger; Stephen P Luby; Emily S Gurley; Umesh D Parashar Journal: Vaccine Date: 2017-09-20 Impact factor: 3.641
Authors: James A Platts-Mills; Caroline Amour; Jean Gratz; Rosemary Nshama; Thomas Walongo; Buliga Mujaga; Athanasia Maro; Timothy L McMurry; Jie Liu; Estomih Mduma; Eric R Houpt Journal: Clin Infect Dis Date: 2017-10-01 Impact factor: 9.079